The stock of Hepion Pharmaceuticals Inc (HEPA) has gone up by 6.89% for the week, with a -26.24% drop in the past month and a -96.28% drop in the past quarter. The volatility ratio for the week is 27.64%, and the volatility levels for the past 30 days are 21.39% for HEPA. The simple moving average for the past 20 days is -0.24% for HEPA’s stock, with a -98.51% simple moving average for the past 200 days.
Is It Worth Investing in Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Right Now?
HEPA has 36-month beta value of 1.92. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for HEPA is 10.88M, and currently, short sellers hold a 4.12% ratio of that float. The average trading volume of HEPA on May 13, 2025 was 4.67M shares.
HEPA) stock’s latest price update
Hepion Pharmaceuticals Inc (NASDAQ: HEPA)’s stock price has decreased by -18.79 compared to its previous closing price of 0.39. However, the company has seen a 6.89% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-12 that MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public shell. The Notice indicated that trading in the Company’s shares of common stock (the “Common Stock”) on Nasdaq will be suspended effective at the open of trading on Tuesday, May 13, 2025.
Analysts’ Opinion of HEPA
Many brokerage firms have already submitted their reports for HEPA stocks, with ROTH Capital repeating the rating for HEPA by listing it as a “Buy.” The predicted price for HEPA in the upcoming period, according to ROTH Capital is $14 based on the research report published on July 20, 2020 of the previous year 2020.
HEPA Trading at -71.34% from the 50-Day Moving Average
After a stumble in the market that brought HEPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.54% of loss for the given period.
Volatility was left at 21.39%, however, over the last 30 days, the volatility rate increased by 27.64%, as shares sank -24.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -94.95% lower at present.
During the last 5 trading sessions, HEPA rose by +6.89%, which changed the moving average for the period of 200-days by -99.15% in comparison to the 20-day moving average, which settled at $0.3188. In addition, Hepion Pharmaceuticals Inc saw -98.65% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HEPA
The total capital return value is set at 12.64. Equity return is now at value -487.03, with -133.45 for asset returns.
Based on Hepion Pharmaceuticals Inc (HEPA), the company’s capital structure generated 2.8 points at debt to capital in total, while cash flow to debt ratio is standing at -6.28. The debt to equity ratio resting at -1.56. The interest coverage ratio of the stock is -4448.51.
Currently, EBITDA for the company is -19.35 million with net debt to EBITDA at -0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.51.
Conclusion
To put it simply, Hepion Pharmaceuticals Inc (HEPA) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
